^
Association details:
| Biomarker: | LDH elevation |
|---|---|
| Cancer: | Marginal Zone Lymphoma |
| Regimen: | (lenalidomide + Venclexta (venetoclax) + Gazyva (obinutuzumab) + Imbruvica (ibrutinib) + prednisone) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
598 Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
Published date:
11/04/2020
Excerpt:
53 pts were enrolled and treated; 17 in dose-escalation and 36 in dose-expansion. NHL subtypes included DLBCL (23), FL (19), HGBCL “double-hit” (9), and MZL (2). Of 32 aggressive pts, 34% transformed from indolent NHL. Median age was 57y (range 29-83) with stage III/IV disease in 89%, elevated LDH in 68%, and >2 EN sites in 57%...Of 53 total patients, 51 completed 1C of therapy with restaging CT and tumor reduction occurred in 90% of pts overall... ViPOR induces durable CRs without maintenance therapy, including refractory and post CAR-T...
Secondary therapy:
prednisone
